Travere Therapeutics announced that CEO Eric Dube, Ph.D., will step down, citing a need to focus on his health and family. Dube led the company through a significant transformation, including a rebranding and the successful launch of Filspari, a treatment for a rare kidney disease. His departure marks the end of a tenure defined by strategic repositioning and commercial execution.
Bradley Campbell, who previously served as CEO of Amicus Therapeutics, will take over the helm at Travere. Campbell brings extensive experience in the rare disease space, which aligns with Travere's focus. The leadership transition appears orderly, with Campbell stepping in as Dube departs.
The source does not provide additional details on the timeline or any interim arrangements, but the announcement signals continuity in the company's mission. Dube's exit underscores the personal toll that leading a biotech can take, even amid professional successes.